Vp, Group Scientific Director
Current• A senior strategic scientific lead on a major immune-oncology (IO) therapeutic for US and Global Medical Affairs, and the Commercial group for medical education and communication activities• Oversee scientific and clinical content development for IO account, and develop key strategic recommendations for IO therapeutic• Launched in US IO therapy for bladder cancer and non-small cell lung cancer (NSCLC) for both Medical Affairs and Commercial groups• Oversee content for global launch of IO therapy• Managed, recruited, mentored Scientific and Senior Directors on IO account• Developed strategic and tactical plans for Medical Affairs and Commercial IO groups• Contributed to new business development and strategic planning• Member of Lockwood Senior Management Team